-
Mashup Score: 157
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hep…
Source: www.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 215
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibit…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: https://t.co/dZPaihNNp6 #ESCardio https://t.co/ESVx2rsYv6
-
-
Mashup Score: 121
Whether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non–ST-segment elevation myocardial infarct…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
Presented at #ESCardio: Among older patients with non–ST-segment elevation myocardial infarction (MI), an invasive strategy did not result in a lower risk of cardiovascular death or nonfatal MI than a conservative strategy. Full SENIOR-RITA trial results: https://t.co/ZhKdVsJrhs https://t.co/LfCre1p33x
-
-
Mashup Score: 156
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hep…
Source: www.nejm.orgCategories: General Medicine News, General Journals & SocietTweet-
Presented at #ESCardio: Among patients with transthyretin amyloidosis with cardiomyopathy, the risk of death from any cause and recurrent cardiovascular events was lower with vutrisiran treatment than with placebo. Full HELIOS-B trial results: https://t.co/3MZy3lLznK https://t.co/8bsrrRMDkb
-
-
Mashup Score: 215
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibit…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: https://t.co/dZPaihNNp6 #ESCardio https://t.co/ESVx2rsYv6
-
-
Mashup Score: 215
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibit…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: https://t.co/dZPaihNNp6 #ESCardio https://t.co/ESVx2rsYv6
-
-
Mashup Score: 153Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease | NEJM - 29 day(s) ago
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary a…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
EPIC-CAD: In a multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. https://t.co/13c46bpne0 #ESCardio https://t.co/kUujCUy6rv
-
-
Mashup Score: 153Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease | NEJM - 1 month(s) ago
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary a…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
EPIC-CAD: In a multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. https://t.co/13c46bpne0 #ESCardio https://t.co/kUujCUy6rv
-
-
Mashup Score: 153Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease | NEJM - 1 month(s) ago
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary a…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
EPIC-CAD: In a multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. https://t.co/13c46bpne0 #ESCardio https://t.co/kUujCUy6rv
-
-
Mashup Score: 165Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women | NEJM - 1 month(s) ago
High-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels contribute to 5-year and 10-year predictions of cardiovascular risk and represent dis…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
Presented at #ESCardio: Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovascular disease risk among women enrolled in the Women’s Health Study. Full study results: https://t.co/SJvckaaab7 https://t.co/7lqtR1xDA3
-
Presented at #ESCardio: Among patients with transthyretin amyloidosis with cardiomyopathy, the risk of death from any cause and recurrent cardiovascular events was lower with vutrisiran treatment than with placebo. Full HELIOS-B trial results: https://t.co/3MZy3lLznK https://t.co/8bsrrRMDkb